Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 2,339 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,339 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total value of $38,593.50. Following the completion of the sale, the insider now owns 176,952 shares of the company’s stock, valued at approximately $2,919,708. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, September 3rd, Soleil Boughton sold 2,345 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.65, for a total value of $34,354.25.
• On Tuesday, August 6th, Soleil Boughton sold 2,334 shares of Hims & Hers Health stock. The stock was sold at an average price of $17.30, for a total transaction of $40,378.20.
• On Tuesday, July 23rd, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.29, for a total transaction of $47,377.15.
• On Tuesday, July 9th, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.28, for a total transaction of $47,353.80.

Hims & Hers Health Stock Down 1.1 %

HIMS stock traded down $0.18 during midday trading on Tuesday, reaching $16.10. The stock had a trading volume of 5,079,143 shares, compared to its average volume of 7,771,740. The firm has a market cap of $3.46 billion, a price-to-earnings ratio of -1,610.00 and a beta of 1.05. Hims & Hers Health, Inc. has a twelve month low of $5.65 and a twelve month high of $25.74. The business has a fifty day simple moving average of $17.62 and a two-hundred day simple moving average of $17.05.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The company had revenue of $315.65 million during the quarter, compared to analysts’ expectations of $302.43 million. During the same quarter in the previous year, the company earned ($0.03) EPS. Hims & Hers Health’s revenue was up 51.8% on a year-over-year basis. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in Hims & Hers Health by 1.0% in the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock valued at $221,379,000 after purchasing an additional 136,907 shares in the last quarter. Renaissance Technologies LLC raised its stake in Hims & Hers Health by 113.1% during the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after buying an additional 3,205,108 shares during the period. Dimensional Fund Advisors LP grew its stake in Hims & Hers Health by 9.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock valued at $19,117,000 after acquiring an additional 193,507 shares during the period. Farallon Capital Management LLC raised its position in shares of Hims & Hers Health by 3,890.5% during the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after purchasing an additional 1,634,000 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Hims & Hers Health by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,294,759 shares of the company’s stock valued at $11,523,000 after purchasing an additional 22,009 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Needham & Company LLC started coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. Piper Sandler restated a “neutral” rating and issued a $18.00 target price on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Canaccord Genuity Group increased their target price on shares of Hims & Hers Health from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, May 22nd. Citigroup downgraded shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and lifted their price target for the company from $16.00 to $20.00 in a report on Wednesday, May 22nd. Finally, Bank of America decreased their price objective on shares of Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday. Eight analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.86.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.